Skip to content

Study · Animal study (in vivo) · dog · 2021

6 results

Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog.

Terse PS, Peggins J, Seminara SB

International journal of toxicology14 Jun 2021Cited by 2 (Europe PMC)

PMID34126799 (opens in a new tab)PMCIDPMC8277707 (opens in a new tab)DOI10.1177/10915818211023459 (opens in a new tab)PepBankPUB-34126799
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In dogs given KP-10 intravenously once daily for 14 days, there were no overt signs of drug-related toxicity in clinical signs, body weights, food consumption, pathology or other safety measures.

    In plain wordsIn dogs, daily kisspeptin‑10 for 14 days caused no clear signs of toxicity in the safety checks that were done.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeDrug-related toxicity signs
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    There were no overt signs of drug-related toxicity observed in clinical signs, body weights, food consumption, clinical pathology, histopathology, urinalysis, electrocardiogram, or respiratory rate.
    1 context sentence
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, the LH response to KP-10 peaked 5 minutes after dosing and stayed relatively unchanged for at least 30 minutes, with no gender effect.

    In plain wordsIn dogs, luteinizing hormone peaked 5 minutes after kisspeptin‑10 and stayed high for at least 30 minutes, in both sexes.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH response time course (surrogate for exposure)
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Measurements

    Time of maximum LH concentration
    5 min
    post-dose

    Source sentences

    Summary
    Due to very rapid clearance of the peptide, luteinizing hormone (LH) levels were measured as a surrogate marker to demonstrate KP-10 exposure.
    2 context sentences
    Summary · context
    The LH response reached a maximum concentration at 5 minutes post-dose and remained relatively unchanged for at least 30 minutes after dosing with no gender effect.
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, LH concentrations on Day 1 were generally greater than on day 14.

    In plain wordsIn dogs, the luteinizing hormone response was generally smaller on day 14 than on day 1.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseLH concentration on Day 1 versus day 14
    Study

    dogn: not reported in source

    Comparator
    Day 1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    LH concentrations on Day 1 were generally greater than on day 14.
    1 context sentence
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In dogs given KP-10, vaginal cytology showed all dogs stayed in anestrous during dosing.

    In plain wordsIn dogs, vaginal tests showed that all dogs stayed in anestrus during kisspeptin‑10 dosing.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeVaginal cytology (estrous stage)
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    Vaginal cytology results indicated all dogs were in anestrous throughout the dosing period.
    1 context sentence
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In dogs, no KP-10-related findings were seen in recovery animals on Day 29.

    In plain wordsIn dogs, no kisspeptin‑10-related findings were seen after the recovery period.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeFindings in recovery animals on Day 29
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    There were also no KP-10-related findings observed in recovery animals on Day 29.
    1 context sentence
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In dogs, the 1,000 μg/kg dose of KP-10 given intravenously once daily for 14 days was considered the no-observed-adverse-effect level.

    In plain wordsIn dogs, the highest dose tested of kisspeptin‑10 caused no observed harmful effects over 14 days.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeNo-observed-adverse-effect level
    Study

    dogn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30, 100 and 1,000 μg/kg · intravenous · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    In conclusion, KP-10 demonstrated favorable safety profile in dog where 1,000 μg/kg dose was considered as a no-observed-adverse-effect level dose when administered IV once daily for 14 days.
    1 context sentence
    Summary · context
    A safety evaluation of KP-10 was conducted in dogs at the doses of 30, 100, and 1,000 μg/kg, given once daily intravenously for 14 days with a 14-day recovery period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.